Effect of high doses of vitamin D supplementation on dengue virus replication, Toll-like receptor expression, and cytokine profiles on dendritic cells
Molecular and Cellular Biochemistry, pp 1–12 https://doi.org/10.1007/s11010-019-03658-w
Jahnnyer Martínez-MorenoJuan C. HernandezSilvio Urcuqui-Inchima
Appears that they gave 4,000 IU of vitamin D for only 10 days
Then added Dengu Virus to sampled blood
Virus category starts with the following
see alsoImmunity, Ebola, HIV, Influenza Hepatitis B Hepatitis-C,
Rotavirus, Shingles Enveloped Virus Virus-Pregnancy category has
Many viruses can apparently be dealt with by:
- Vaccination (if avaiable & affordable and person is willing to have the side-effects - which can include death)
- Getting Vitamin D into your blood
- Increasing the vitamin D actually getting to cells Magnesium, Omega-3, Resveratrol, etc
Especially enveloped viruses", Herpes, Zoster, Epstein, Hepatitis, Ebola, Dengue, Yellow fever, Measles, Mumps, smallpox, HIV
Dengue, caused by dengue virus (DENV) infection, is a public health problem worldwide. Although DENV pathogenesis has not yet been fully elucidated, the inflammatory response is a hallmark feature in severe DENV infection. Although vitamin D (vitD) can promote the innate immune response against virus infection, no studies have evaluated the effects of vitD on DENV infection, dendritic cells (DCs), and inflammatory response regulation. This study aimed to assess the impact of oral vitD supplementation on DENV-2 infection, Toll-like receptor (TLR) expression, and both pro- and anti-inflammatory cytokine production in monocyte-derived DCs (MDDCs).
To accomplish this, 20 healthy donors were randomly divided into two groups and received either 1000 or 4000 international units (IU)/day of vitD for 10 days. During pre- and post-vitD supplementation, peripheral blood samples were taken to obtain MDDCs, which were challenged with DENV-2. We found that MDDCs from donors who received 4000 IU/day of vitD were less susceptible to DENV-2 infection than MDDCs from donors who received 1000 IU/day of vitD. Moreover, these cells showed decreased mRNA expression of TLR3, 7, and 9; downregulation of IL-12/IL-8 production; and increased IL-10 secretion in response to DENV-2 infection.
In conclusion, the administration of 4000 IU/day of vitD decreased DENV-2 infection. Our findings support a possible role of vitD in improving the innate immune response against DENV. However, further studies are necessary to determine the role of vitD on DENV replication and its innate immune response modulation in MDDCs.
|1575 visitors, last modified 03 Feb, 2020,